# ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Source: https://onco.cc/trials/nct07342478/  
OnCo record `nct07342478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Rocbrutinib in chronic lymphocytic leukaemia, now recruiting.

## Summary

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL is a phase 3 interventional study registered as NCT07342478, led by Newave Pharmaceutical, and recruiting on the registry. Official title: A Phase 3 Open-Label, Randomised, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects. Planned enrolment is 306 participants (estimated). The study started in 2026-04-23 and primary completion is expected in 2029-10-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07342478
- Phase: 3
- Setting: A Phase 3 Open-Label, Randomized, Multicenter Study of Rocbrutinib (LP-168) vs Pirtobrutinib in Covalent BTK Inhibitor (cBTKi) Pretreated Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) Subjects
- Sponsor: Newave Pharmaceutical
- Enrolled: 306

## Sources

- ClinicalTrials.gov NCT07342478: https://clinicaltrials.gov/study/NCT07342478

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Relapsed or refractory chronic lymphocytic leukaemia](https://onco.cc/cancers/cll-relapsed/)
- drugs: [Rocbrutinib](https://onco.cc/drugs/rocbrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct07342478.json